Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences

Eliel Bayever, Kathleen M. Haines, Patrick L. Iversen, Raymond W. Ruddon, Samuel J. Pirruccello, Charles P. Mountjoy, Mark A. Arneson, Larry J. Smith

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Cells were treated in vitro with oligodeoxyribonucleotide phosphorothioates (ODNs) complementary to sites common to both wild-type and mutant p53 nucleotide sequences. Acute myelogenous leukemia (AML) blasts from peripheral blood were exposed to four different p53 ODNs and showed anti-leukemic effects in suspension culture. This effect continued after removal of the ODN from the medium. Blocking of self-renewal of the leukemic blast stem cells in secondary plating of cells from cloning assays by two of the p53 ODNs was also observed. Control ODNs had no effect on leukemic blasts. Treatment of normal bone marrow cells with the four p53 ODNs did not influence their growth, nor was there any effect by the p53 ODNs on the leukemic cell-line, HL60, that does not express p53. These data suggest that p53 ODNs are selectively toxic to primary myelogenous blasts and may be therapeutically useful in AML.

Original languageEnglish (US)
Pages (from-to)223-231
Number of pages9
JournalLeukemia and Lymphoma
Volume12
Issue number3-4
DOIs
StatePublished - 1994

Keywords

  • Human myeloid leukemia
  • Oligonucleotide
  • P53

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences'. Together they form a unique fingerprint.

  • Cite this